Adial Pharmaceuticals Announces Database Lock In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder; Topline Results Expected In Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Adial Pharmaceuticals has announced the database lock in its pharmacokinetics study of AD04, a treatment for Alcohol Use Disorder. The company expects to release topline results in Q4 2024.
September 19, 2024 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adial Pharmaceuticals has completed a significant milestone in its study of AD04 for Alcohol Use Disorder by locking the database. This step is crucial for the analysis and release of topline results expected in Q4 2024.
The database lock is a critical step in clinical trials, indicating that data collection is complete and analysis can begin. This progress could positively influence investor sentiment as it shows advancement towards potential approval and commercialization of AD04.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100